


Product Data Sheet

| | | | |
|--|--|--------------|---------|
| Cas No.: | 741713-40-6 | Cat. No: | PL01027 |
| Product Name: | R547 | | |
| Product synonym: | [4-氨基-2-[(1-甲磺酰基哌啶-4-基)氨基]嘧啶-5-基](2,3-二氟-6-甲氧基苯基)甲酮; [4-氨基-2-[(1-甲磺酰基哌啶-4-基)氨基]嘧啶-5-基](2,3-二氟-6-甲氧基苯基)甲酮 | | |
| Chemical name: | R547 | | |
| MF: | C18H21F2N5O4S | FW: | 441.45 |
| Purity: | ≥98% | Batch No.: | - |
| Storage: | | | |
| Structural formula: |  | | |
| λmax: | - | Formulation: | - |
| Solubility : | | | |
| SMILES : | O=S(N1CCC(NC2=NC(N)=C(C(C3=C(C(F)=CC=C3OC)F)=O)C=N2)CC1)(C)=O | | |
| InChI Code: | - | | |
| InChI Key: | | | |
| WARNING This product is not for human or veterinary use. | | | |

Product Description

R547 是一种高效、选择性的，口服有效的 ATP 竞争性的 CDK 抑制剂，对 CDK1/cyclin B、CDK2/cyclin E 和 CDK4/cyclin D1 作用的 K_i 值分别为 2 nM、3 nM、1 nM。

| | |
|---------------------|---|
| 生物活性 | R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with K_i s of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively. |
| IC50 & Target[1][2] | Cdk1/cyclin B 2 nM (K_i) CDK2/cyclinE 3 nM (K_i) |

| | |
|----------------|---|
| 体外研究(In Vitro) | <p>R547 effectively inhibits CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1 ($K_i = 1-3 \text{ nmol/L}$) and is inactive ($K_i > 5,000 \text{ nmol/L}$) against a panel of >120 unrelated kinases in cell-free assays.</p> <p>R547 effectively inhibits the proliferation of tumor cell lines independent of multidrug resistant status, histologic type, retinoblastoma protein, or p53 status, with IC_{50}s $<0.60 \mu\text{M}$.</p> <p>R547 reduces phosphorylation of the cellular retinoblastoma protein at specific CDK phosphorylation sites at the same concentrations that induced cell cycle arrest.</p> <p>R547 has anti-proliferative activity in tumor cells independent of p53, retinoblastoma, or MDR status.</p> <p>R547 blocks tumor cells in G1 plus G2 and induces apoptosis.</p> <p>R547 induces apoptosis as measured by DNA fragmentation.</p> <p>R547 inhibits phosphorylation of retinoblastoma protein in human tumor cells.</p> |
| 体内研究(In Vivo) | <p>R547 has significant in vivo efficacy with daily oral and once weekly i.v. dosing.</p> <p>R547 inhibits phosphorylation of retinoblastoma protein in tumors.</p> <p>has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:</p> |
| 包装储存 | Powder -20°C 3 years; 4°C 2 years |